Find Research Outputs

Search in all content

Filters for Research Output

Search concepts
Selected filters

Publication Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Author

  • Michael Millward

PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study

Khattak, M. A., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M. H., Meniawy, T., Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M. & Gray, E., 5 Dec 2019, In : The Oncologist.

Research output: Contribution to journalArticle

Open Access
4 Citations (Scopus)
18 Citations (Scopus)

Pembrolizumab versus ipilimumab in advanced melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N. & 3 others, Ebbinghaus, S., Ribas, A. & Millward, M., 25 Jun 2015, In : New England Journal of Medicine. 372, 26, p. 2521-2532 12 p.

Research output: Contribution to journalArticle

Open Access
2807 Citations (Scopus)

PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples

Winterhoff, B., Freyer, L., Hammond, E., Giri, S. S., Mondal, S., Roy, D. K., Teoman, A., Mullany, S. A., Hoffmann, R., Von Bismarck, A., Chien, J., Block, M. S., Millward, M., Bampton, D., Dredge, K. & Shridhar, V., 2015, In : European Journal of Cancer. 51, 7, p. 879-892

Research output: Contribution to journalArticle

34 Citations (Scopus)

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Millward, M., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., Longenecker, A., Lee, L., Lay, A., Sharma, G., Gemmill, R. M., Drabkin, H. A., Lloyd, G. K., Neuteboom, S. T. C., Mcconkey, D. J., Palladino, M. A. & Spear, M. A., 2012, In : Investigational New Drugs. 30, p. 2303–2317

Research output: Contribution to journalArticle

92 Citations (Scopus)

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

Millward, M., Mainwaring, P., Mita, A., Federico, K., Lloyd, G. K., Reddinger, N., Nawrocki, S., Mita, M. & Spear, M. A., 2012, In : Investigational New Drugs. 30, p. 1065-1073

Research output: Contribution to journalArticle

43 Citations (Scopus)

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai, J., Gan, H., Barrow, C., Jameson, M., Atkinson, V., Haydon, A., Millward, M., Begbie, S., Brown, M., Markman, B., Patterson, W., Hill, A., Horvath, L., Nagrial, A., Richardson, G., Jackson, C., Friedlander, M., Parente, P., Tran, B., Wang, L. & 7 others, Chen, Y., Tang, Z., Huang, W., Wu, J., Zeng, D., Luo, L. & Solomon, B., 17 Mar 2020, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. p. JCO1902654

Research output: Contribution to journalArticle

Open Access

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumours

Desai, J., Deva, S., Lee, J. S., Lin, C-C., Yen, C-J., Chao, Y., Keam, B., Jameson, M., Hou, M-M., Kang, Y-K., Markman, B., Lu, C-H., Rau, K-M., Lee, K-H., Horvath, L., Friedlander, M., Hill, A., Sandhu, S., Barlow, P., Wu, C-Y. & 5 others, Zhang, Y., Liang, L., Wu, J., Paton, V. & Millward, M., Jun 2020, In : Journal for ImmunoTherapy of Cancer . 8, 1

Research output: Contribution to journalArticle

Open Access

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L. & Hughes, B. G. M., Feb 2018, In : Targeted Oncology. 13, 1, p. 89-98 10 p.

Research output: Contribution to journalArticle

15 Citations (Scopus)

Phase i clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: Study NPI-0052-102 final results

Harrison, S. J., Mainwaring, P., Price, T., Millward, M., Padrik, P., Underhill, C. R., Cannell, P. K., Reich, S. D., Trikha, M. & Spencer, A., 2016, In : Clinical Cancer Research. 22, 18, p. 4559-4566

Research output: Contribution to journalArticle

32 Citations (Scopus)

Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., Mcarthur, G. A., Hwu, P., Gonzalez, R., Ott, P. A., Long, G. V., Gardner, O. S., Ouellet, D., Xu, Y., Demarini, D. J., Le, N. T., Patel, K. & Lewis, K. D., 2013, In : Journal of Clinical Oncology. 31, 4, p. 482-489

Research output: Contribution to journalArticle

323 Citations (Scopus)

Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study

Lam, W., Nowak, A., Chen, F., Muruganandan, S., Arunachalam, S., Chin, M., Millward, M., Read, C., Murray, K., Creaney, J. & Lee, Y. C. G., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. S342-S342 1 p.

Research output: Contribution to journalAbstract/Meeting Abstract

Phase i study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

Millward, M., Underhill, C., Lobb, S., Mcburnie, J., Meech, S. J., Gomez-Navarro, J., Marshall, M. A., Huang, B. & Mather, C. B., 2013, In : British Journal of Cancer. 108, 10, p. 1998-2004

Research output: Contribution to journalArticle

Open Access
45 Citations (Scopus)

Positive sentinel lymph node metastasis from a metastasis in Melanoma

Bowyer, S. E., Feeney, K. T. & Millward, M., 2014, In : Asia-Pacific Journal of Clinical Oncology. 10, 4, p. 376-377

Research output: Contribution to journalArticle

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Woodford, R., Loh, Y., Lee, J., Cooper, W., Marschner, I., Lewis, C. R., Millward, M., Lord, S., Gralla, R. J., Yang, J. C-H., Mok, T. & Lee, C. K., Jul 2019, In : Future Oncology. 15, 20, p. 2371-2383 13 p.

Research output: Contribution to journalReview article

Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma

Dunkel, Y., Reid, A. L., Ear, J., Aznar, N., Millward, M., Gray, E., Pearce, R., Ziman, M. & Ghosh, P., 1 Dec 2018, In : Scientific Reports. 8, 1, 18036.

Research output: Contribution to journalArticle

Open Access
2 Citations (Scopus)

Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features

Ye, L., Leslie, C., Jacques, A., Ardakani, N. M., Amanuel, B. & Millward, M., Apr 2019, In : Modern Pathology. 32, 4, p. 524-531 8 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma

Parakh, S., Randhawa, M., Nguyen, B., Warburton, L., Hussain, M. A., Cebon, J., Millward, M., Yip, D. & Ali, S., 13 Nov 2018, In : Asia–Pacific Journal of Clinical Oncology.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M. C., Parakh, S., Cebon, J., Long, G. V., Carlino, M. S. & Klein, O., 11 Apr 2017, In : British Journal of Cancer. 116, 8, p. e15

Research output: Contribution to journalLetter

Open Access
1 Citation (Scopus)

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Cebon, J. S., Gore, M., Thompson, J. F., Davis, I. D., McArthur, G. A., Walpole, E., Smithers, M., Cerundolo, V., Dunbar, P. R., MacGregor, D., Fisher, C., Millward, M., Nathan, P., Findlay, M. P. N., Hersey, P., Evans, T. R. J., Ottensmeier, C. H., Marsden, J., Dalgleish, A. G., Corrie, P. G. & 13 others, Maria, M., Brimble, M., Williams, G., Winkler, S., Jackson, H. M., Endo-Munoz, L., Tutuka, C. S. A., Venhaus, R., Old, L. J., Haack, D., Maraskovsky, E., Behren, A. & Chen, W., 20 Apr 2020, In : Journal for ImmunoTherapy of Cancer . 8, 1, e000410.

Research output: Contribution to journalArticle

Open Access

Role of endobronchial ultrasound in diagnosis and molecular assessment of metastatic melanoma

Jennings, B. R., Millward, M., Amanuel, B., Mulrennan, S., Joosten, S. A. & Phillips, M. J., 2012, In : Respirology. 17, 17, p. 991-996

Research output: Contribution to journalArticle

11 Citations (Scopus)

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study

Khattak, M. A., Abed, A., Reid, A. L., McEvoy, A. C., Millward, M., Ziman, M. & Gray, E. S., 30 Jun 2020, In : Frontiers in Oncology. 10, 1041.

Research output: Contribution to journalArticle

Open Access

Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data

Gao, B., Goh, J., Markman, B., Voskoboynik, M., Gan, H. K., Coward, J., Palmieri, D., So, J., Meniawy, T., Chen, C., Xiang, X., Qiu, J., Xu, Y., Yang, L. & Millward, M., Dec 2019, In : Annals of Oncology. 30, 2 p.

Research output: Contribution to journalAbstract/Meeting Abstract

Safety of immune check-point inhibitors in patients with autoimmune conditions and advanced cancer

Gard, G., Van Hagen, T., Ariyapperuma, M., Feeney, K., Roberts-Thomson, R., Millward, M. & Khattak, M., 1 Oct 2016, In : Annals of Oncology. 27, p. vi371

Research output: Contribution to journalArticle

Open Access
4 Citations (Scopus)
35 Citations (Scopus)

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma

McEvoy, A. C., Calapre, L., Pereira, M. R., Giardina, T., Robinson, C., Khattak, M. A., Meniawy, T. M., Pritchard, A. L., Hayward, N. K., Amanuel, B., Millward, M., Ziman, M. & Gray, E. S., 3 Oct 2017, In : Oncotarget. 8, 45, p. 78890-78900 11 p.

Research output: Contribution to journalArticle

Open Access
20 Citations (Scopus)

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

Zemek, R., de Jong, E., Chin, M., Schuster, I., Fear, V., Casey, T., Forbes, C., Dart, S., Leslie, C., Zaitouny, A., Small, M., Boon, L., Forrest, A. R. R., O Muiri, D., Degli-Esposti, M., Millward, M., Nowak, A., Lassmann, T., Bosco, A., Lake, R. & 1 others, Lesterhuis, W., 17 Jul 2019, In : Science Translational Medicine. 11, 501, 14 p., eaav7816.

Research output: Contribution to journalArticle

Open Access
File
18 Citations (Scopus)
707 Downloads (Pure)

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M. J., Lake, R. A. & Lesterhuis, W. J., 18 Feb 2020, In : Frontiers in Immunology. 11, 223.

Research output: Contribution to journalReview article

Open Access
3 Citations (Scopus)

Sentinel node biopsy for melanoma: The medical oncology perspective

Menzies, A. M., Atkinson, V. G., Brown, M. P., Carlino, M. S., Cebon, J., Guminski, A., Kefford, R. F., Long, G. V., McArthur, G., McNeil, C. M., Millward, M. & Sandhu, S., 1 Jan 2015, In : Australian Family Physician. 44, 12, p. 875-876 2 p.

Research output: Contribution to journalLetter

1 Citation (Scopus)

Serological Biomarkers in Melanoma

Ziman, M., Millward, M., Pearce, R. & Lee, M., 1 Jan 2012, Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Murphy, M. J. (ed.). United States: Springer Dordrecht Heidelberg New York, p. 195-208 14 p.

Research output: Chapter in Book/Conference paperChapter

SEROUS RETINAL DETACHMENT DUE TO FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR IN MALIGNANT PLEURAL MESOTHELIOMA

Arunachalam, S., Lam, W-S., Nowak, A., Creaney, J., Millward, M., Muruganandan, S., Read, C., Lee, G. & Chen, F., Oct 2017, In : Clinical & Experimental Ophthalmology. 45, p. 135-135 1 p.

Research output: Contribution to journalAbstract/Meeting Abstract

8 Citations (Scopus)

Small cell lung cancer presenting with paraneoplastic limbic encephalitis

Bowyer, S., Webb, S., Millward, M., Jasas, K., Blacker, D. & Nowak, A., 2011, In : Asia Pacific Journal of Clinical Oncology. 7, p. 180-184

Research output: Contribution to journalArticle

7 Citations (Scopus)

Small cell lung cancer update

Ferraro, D. & Millward, M., 2013, In : Cancer Forum. 37, 2, p. 5pp

Research output: Contribution to journalArticle

1 Citation (Scopus)
34 Citations (Scopus)

Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia

Lee, Y. C., Kroon, R., Koczwara, B., Haines, I., Francis, K., Millward, M., Kefford, R., Olver, I. & Mileshkin, L., 1 Aug 2017, In : Internal Medicine Journal. 47, 8, p. 888-893 6 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial

Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T. E., Bosquée, L., Trigo, J. M., Spira, A., Tremblay, L., Nyman, J., Ramlau, R., Wickart-Johansson, G., Ellis, P., Gladkov, O., Pereira, J. R., Eberhardt, W. E. E., Helwig, C. & 3 others, Schröder, A., Shepherd, F. A. & Millward, M., 1 Jan 2014, In : LANCET ONCOLOGY. 15, 1, p. 59-68 10 p., PMID 24331154.

Research output: Contribution to journalArticle

266 Citations (Scopus)

Testing for human papillomavirus in BRAF inhibitor-associated verrucous keratoses

Clynick, B., Tabone, T., Heel, K., Erber, W., Wood, B., Millward, M. & Harvey, N., 2014, In : Journal of Cutaneous Pathology. 42, 1, p. 73-75

Research output: Contribution to journalLetter

3 Citations (Scopus)

The aggregation of early-onset melanoma in young Western Australian families

Ward, S., Dowty, J. G., Webster, R., Cadby, G., Glasson, E., Heyworth, J., Emery, J., Cole, J. M., Millward, M., Wood, F. & Palmer, L. J., 2015, In : Cancer Epidemiology. 39, 3, p. 346-352

Research output: Contribution to journalArticle

1 Citation (Scopus)
8 Citations (Scopus)
Open Access

The effects of phenoxodiol on the cell cycle of prostate cancer cell lines

Mahoney, S., Arfuso, F., Millward, M. & Dharmarajan, A., 2014, In : Cancer Cell International. 14, p. 1-12

Research output: Contribution to journalArticle

Open Access
10 Citations (Scopus)

The Western Australian Melanoma Health Study: Study design and participant characteristics

Ward, S., Cadby, G., Lee, A., Cole, J. M., Heyworth, J., Millward, M., Wood, F. & Palmer, L. J., 2011, In : Cancer Epidemiology. 35, p. 423-431

Research output: Contribution to journalArticle

5 Citations (Scopus)

Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

Itchins, M., Chia, P. L., Hayes, S. A., Howell, V. M., Gill, A. J., Cooper, W. A., John, T., Mitchell, P., Millward, M., Clarke, S. J., Solomon, B. & Pavlakis, N., 1 Aug 2017, In : Asia-Pacific Journal of Clinical Oncology. 13, p. 3-13 11 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)

Nathanson, K. L., Martin, A-M., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J. R., Falchook, G. S., Arkenau, H-T., Millward, M., Brown, M. P., Pavlick, A., Davies, M. A., Ma, B., Gagnon, R., Curtis, M., Lebowitz, P. F., Kefford, R. & Long, G. V., 2013, In : Clinical Cancer Research. 19, 17, p. 4868-4878

Research output: Contribution to journalArticle

Open Access
107 Citations (Scopus)
2 Citations (Scopus)
1 Citation (Scopus)

Wnt Antagonist, Secreted Frizzled-Related Protein 4 (sFRP4), Increases Chemotherapeutic Response of Glioma Stem-Like Cells

Warrier, S., Balu, S. K., Kumar, A., Millward, M. & Dharmarajan, A., 2014, In : Oncology Research. 21, p. 93-102

Research output: Contribution to journalArticle

41 Citations (Scopus)